Psilocin–Psilocybin Co-Crystal for Stability and Rapid Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing studies on psilocin are limited due to its chemical instability, and there is a lack of comprehensive understanding of its effects compared to psilocybin, necessitating a compound that combines both to leverage their unique and beneficial properties for treating neuropsychiatric, neurological, and inflammatory disorders, as well as cancer, while minimizing cardiac adverse events.
Innovation Solution
A co-crystal form of psilocybin and psilocin, characterized by specific XRPD patterns, is administered to subjects to treat disorders, induce neuroplasticity, stimulate neuronal growth, increase neuronal progenitor cells, and reduce neuroinflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If psilocin is used alone to achieve faster absorption and more rapid onset of action, then the onset speed is improved, but chemical stability deteriorates due to rapid oxidation when exposed to air
Solution Approach 1:
The patent combines psilocin and psilocybin into a single co-crystal formulation. This merging allows the composition to exhibit both the rapid onset properties of psilocin and the stability of psilocybin, resolving the contradiction between speed and stability. The co-crystal structure integrates both compounds in a fixed ratio, enabling them to work synergistically while maintaining chemical stability during storage and handling.
Solution Approach 2:
The invention creates a composite material in the form of a co-crystal containing both psilocin and psilocybin. This composite formulation leverages the complementary properties of the two compounds: psilocin provides rapid absorption and onset, while psilocybin contributes chemical stability. The co-crystal structure represents a novel composite that combines these materials at the molecular level, achieving properties superior to either compound alone.
2Stability of the object's composition
If psilocybin is used to achieve chemical stability, then stability is improved, but absorption rate and onset of action deteriorate compared to psilocin
Solution Approach 1:
The co-crystal formulation merges psilocybin (stable but slow-acting) with psilocin (unstable but fast-acting) in a fixed 1:1 molar ratio. This combination allows the composition to achieve rapid absorption comparable to psilocin while maintaining the chemical stability of psilocybin, effectively resolving the contradiction between stability and absorption rate.
Solution Approach 2:
The patent creates a composite co-crystal material that integrates psilocybin and psilocin at the molecular level. This composite formulation enables the material to exhibit enhanced dissolution and absorption characteristics compared to pure psilocybin, while maintaining chemical stability. The synergistic interaction between the two compounds in the co-crystal structure overcomes the limitation of slow absorption associated with psilocybin alone.
3Reliability
If a co-crystal combining psilocin and psilocybin is used to leverage unique and beneficial properties, then therapeutic efficacy is improved, but formulation complexity increases
Solution Approach 1:
The invention merges two active compounds into a single co-crystal phase, simplifying the formulation compared to using separate compounds. The fixed 1:1 molar ratio in the co-crystal structure eliminates the need for separate dosing and formulation of each compound, reducing formulation complexity while maintaining enhanced therapeutic efficacy through synergistic action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The co-crystal form effectively treats neuropsychiatric, neurological, and inflammatory disorders, increases BDNF levels, and decreases neuroinflammation, with reduced cardiac risks, demonstrating therapeutic efficacy through increased neuronal growth and progenitor cell numbers.
Implementation Method 1
A co-crystal form of psilocybin and psilocin, characterized by specific XRPD patterns, is administered to subjects to treat disorders
Data Source
AI summary
The present disclosure provides a method of treating or ameliorating a disease or disorder in a subject in need thereof, comprising administering to the subject a composition comprising a crystalline form of psilocin and psilocybin, wherein the crystalline form is co-crystal form A of psilocin and psilocybin. The disclosure further provides methods of stimulating inducing neuroplasticity, increasing BDNF levels, and/or decreasing neuroinflammation.